Immix Biopharma (NASDAQ:IMMX) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings results on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06, Zacks reports.

Immix Biopharma Stock Up 1.6 %

Immix Biopharma stock traded up $0.03 during mid-day trading on Wednesday, hitting $1.89. 55,361 shares of the company’s stock traded hands, compared to its average volume of 205,516. The firm has a 50 day moving average price of $2.10 and a 200 day moving average price of $2.53. The company has a market cap of $49.92 million, a PE ratio of -2.03 and a beta of 0.17. Immix Biopharma has a one year low of $1.55 and a one year high of $7.75.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a report on Friday, July 26th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.